Efficacy of Trametinib in Neurofibromatosis Type 1–Associated Gastrointestinal Stromal Tumors: A Case Report-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy of Trametinib in Neurofibromatosis Type 1–Associated Gastrointestinal Stromal Tumors: A Case Report

Published:2024-08 Issue:8 Volume: Page:
ISSN:2473-4284
Container-title:JCO Precision Oncology
language:en
Short-container-title:JCO Precis Oncol

Author:

Fukuda Misao¹^ORCID,Mukohara Toru¹²^ORCID,Kuwata Takeshi²,Sunami Kuniko³^ORCID,Naito Yoichi¹⁴^ORCID

Affiliation:

1. Department of Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan

2. Department of Genetic Medicine and Services, National Cancer Center Hospital East, Kashiwa, Japan

3. Department of Laboratory Medicine, National Cancer Center Hospital, Tokyo, Japan

4. Department of General Internal Medicine, National Cancer Center Hospital East, Kashiwa, Japan

Abstract

Trametinib, an MEK inhibitor, may offer a new therapeutic option for patients with NF1-related GIST.

Publisher

American Society of Clinical Oncology (ASCO)

Link

https://ascopubs.org/doi/pdfdirect/10.1200/PO.23.00649

Reference25 articles.

1. Neurofibromatosis

2. Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus

3. Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation

4. Comparison of Cancer Prevalence in Patients With Neurofibromatosis Type 1 at an Academic Cancer Center vs in the General Population From 1985 to 2020

5. Malignant and benign tumors in patients with neurofibromatosis type 1 in a defined Swedish population

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP